{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:23:33Z","timestamp":1791235413691,"version":"4.1.0"},"reference-count":24,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is an ideal target for chemoprevention. To date, chemoprevention clinical trials with 5\u03b1-reductase inhibitors have yielded encouraging yet ultimately confounding results. Using a preclinical mouse model of high-grade prostatic intraepithelial neoplasia (HG-PIN) induced by PTEN loss, we observed unprecedented deteriorating effects of androgen deprivation, in which surgical castration or MDV3100 treatment accelerated disease progression of the otherwise stable HG-PIN to invasive castration-resistant prostate cancer (CRPC). As an alternative, targeting the phosphoinositide 3-kinase (PI3K) signaling pathway via either genetic ablation of genes encoding PI3K components or pharmacologic inhibition of the PI3K pathway reversed the PTEN loss\u2013induced HG-PIN phenotype. Finally, concurrent inhibition of the PI3K and mitogen-activated protein kinase (MAPK) pathways was effective in blocking the growth of PTEN-null CRPC. Together, these data have revealed the potential adverse effects of antiandrogen chemoprevention in certain genetic contexts (such as PTEN loss) while showing the promise of targeted therapy in the clinical management of this complex and prevalent disease.<\/jats:p>\n                  <jats:p>Significance: Chemoprevention with antiandrogen therapies is attractive for prostate cancer, given its prevalence and established hormonally mediated pathogenesis. However, because PTEN loss has been found in 9% to 45% of HG-PIN in the clinic, the current findings suggest that patients with PTEN-deficient prostate tumors might be better treated with PI3K-targeted therapies. Cancer Discov; 3(1); 44\u201351. \u00a92012 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 1<\/jats:p>","DOI":"10.1158\/2159-8290.cd-12-0262","type":"journal-article","created":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T01:09:55Z","timestamp":1356138595000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention"],"prefix":"10.1158","volume":"3","author":[{"given":"Shidong","family":"Jia","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Gao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyun","family":"Lee","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sauveur-Michel","family":"Maira","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Stack","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Signoretti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Loda","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean J.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"},{"name":"Authors' Affiliations: Departments of 1Cancer Biology and 2Medical Oncology, Dana-Farber Cancer Institute; Departments of 3Biological Chemistry and Molecular Pharmacology and 4Pathology, Harvard Medical School, \u00adBoston, Massachusetts; and 5Novartis Institutes for BioMedical Research, Inc., Oncology Disease Area, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2013,1,13]]},"reference":[{"key":"2022060623080811700_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3389\/fendo.2012.00072","article-title":"Prostate cancer\u2014a biomarker perspective","volume":"3","author":"Liu","year":"2012","journal-title":"Front Endocrinol"},{"key":"2022060623080811700_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"2022060623080811700_bib3","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060623080811700_bib4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJMe1001045","article-title":"Chemoprevention of prostate cancer","volume":"362","author":"Walsh","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060623080811700_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"2022060623080811700_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer cell"},{"key":"2022060623080811700_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"2022060623080811700_bib8","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2022060623080811700_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<237::AID-PATH224>3.0.CO;2-I","article-title":"Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer","volume":"187","author":"Koivisto","year":"1999","journal-title":"J Pathol"},{"key":"2022060623080811700_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature09677","article-title":"SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression","volume":"470","author":"Ding","year":"2011","journal-title":"Nature"},{"key":"2022060623080811700_bib11","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1126\/science.1189992","article-title":"Identification of a cell of origin for human prostate cancer","volume":"329","author":"Goldstein","year":"2010","journal-title":"Science"},{"key":"2022060623080811700_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"2022060623080811700_bib13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"key":"2022060623080811700_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ceb.2008.12.007","article-title":"Should individual PI3 kinase isoforms be targeted in cancer?","volume":"21","author":"Jia","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"2022060623080811700_bib15","first-page":"279","article-title":"Activation of mitogen-activated protein kinase associated with prostate cancer progression","volume":"59","author":"Gioeli","year":"1999","journal-title":"Cancer Res"},{"key":"2022060623080811700_bib16","doi-asserted-by":"crossref","first-page":"14477","DOI":"10.1073\/pnas.0606836103","article-title":"Combinatorial activities of Akt and B-Raf\/Erk signaling in a mouse model of androgen-independent prostate cancer","volume":"103","author":"Gao","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060623080811700_bib17","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1158\/0008-5472.CAN-05-4143","article-title":"Genetic background controls tumor development in PTEN-deficient mice","volume":"66","author":"Freeman","year":"2006","journal-title":"Cancer Res"},{"key":"2022060623080811700_bib18","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Kinkade","year":"2008","journal-title":"J Clin Invest"},{"key":"2022060623080811700_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cancergencyto.2006.04.003","article-title":"Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias","volume":"169","author":"Yoshimoto","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"2022060623080811700_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/modpathol.2009.69","article-title":"Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression","volume":"22","author":"Han","year":"2009","journal-title":"Mod Pathol"},{"key":"2022060623080811700_bib21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/gcc.20560","article-title":"Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate","volume":"47","author":"Bettendorf","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"2022060623080811700_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/00000478-200108000-00014","article-title":"Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy","volume":"25","author":"Kronz","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"2022060623080811700_bib23","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat Med"},{"key":"2022060623080811700_bib24","doi-asserted-by":"crossref","first-page":"51ra70","DOI":"10.1126\/scitranslmed.3001599","article-title":"Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma","volume":"2","author":"Buonamici","year":"2010","journal-title":"Sci Transl Med"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/1\/44\/1808760\/44.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/3\/1\/44\/1808760\/44.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T19:08:39Z","timestamp":1654542519000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/3\/1\/44\/3661\/Opposing-Effects-of-Androgen-Deprivation-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,13]]},"published-print":{"date-parts":[[2013,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-12-0262","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6545922.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545922","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22529391.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529394.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529394","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529391","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}